IL-13-PE38QQR (Cintredekin besudotox)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IL-13-PE38QQR (Cintredekin besudotox), covering 2014-11-13 to 2014-11-13. Get the full timeline:
Most recent: Clinical Trial Update: Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma [Phase 1, Phase 2]